Idoroenyi Amanam to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Idoroenyi Amanam has written about Leukemia, Myeloid, Acute.
Connection Strength
1.548
-
FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience. J Oncol Pharm Pract. 2026 Apr; 32(3):555-559.
Score: 0.236
-
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
Score: 0.236
-
MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia. J Hematol Oncol. 2025 11 12; 18(1):99.
Score: 0.236
-
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease. Bone Marrow Transplant. 2025 02; 60(2):165-174.
Score: 0.222
-
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol. 2024 08 14; 17(1):67.
Score: 0.217
-
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy. Leuk Lymphoma. 2024 07; 65(7):1020-1023.
Score: 0.212
-
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022 12; 63(13):3232-3236.
Score: 0.189